Effect of resistance training and Epicatechin on Sarcopenia

Improvement of muscle strength and circulatory levels of plasma Follistatin and Myostatin following resistance training and Epicatechin supplementation in sarcopenic older adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017101423002N4

Enrollment

Registered

2017-10-31

Start date

2017-04-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia. -

Interventions

Intervention 1: Exercise+Placebo group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-8

Placebo

Exercise+Placebo group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-80% of one repeti

Placebo group: participants of this group will receive one capsule similar to Epicatechin capsules (in terms of smell and shape) daily with 200 ml water for 8 weeks, at the same time as the supplement

Exercise+supplement group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-80% of one rep

Supplement group: participants of this group consumed one Epicatechin capsule daily (1mg/kg/day) with 200 ml water, at 4 p.m. for 8 weeks.

Eligibility

Sex/Gender

Male

Age

65 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: males between the age of 65-75 years; suffering from class I sarcopenia (AMMI: less than 10.75 kg.m-2); and having no training experiences over the past 12 months before the study. Exclusion criteria: having a history of specific diseases (e.g. valvular heart disease (VHD), ischemic heart disease (IHD); chronic lung disease (COLD); hypertrophic cardiomyopathy (HCM); hyperlipoproteinemia (HLP); hypertension (HTN)); unwillingness to participate in the study; smoking; using supplements or drugs over the past month before the study; suffering from psychological diseases (e.g. mental disorder); and suffering from muscle and joint injuries (e.g. slip disk in the back).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Follistatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.;Myostatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.	—

Secondary

Measure	Time frame
BMI. Timepoint: Before and after the intervention. Method of measurement: weight(kg) / height to the power of 2 (cm).;AMMI. Timepoint: Before and after the intervention. Method of measurement: DXA.;Up and go test. Timepoint: Before and after the intervention. Method of measurement: measuring the test time.;Physical activities rate. Timepoint: Before and after the intervention. Method of measurement: Via The Physical Activity Scale for the Elderly questionnaire /PASE.;Physical health condition. Timepoint: Before and after the intervention. Method of measurement: using PAR-Q questionnaire.;Maximal Strength. Timepoint: Before and after the intervention. Method of measurement: 1RM test.	—

Measure

Time frame

BMI. Timepoint: Before and after the intervention. Method of measurement: weight(kg) / height to the power of 2 (cm).;AMMI. Timepoint: Before and after the intervention. Method of measurement: DXA.;Up and go test. Timepoint: Before and after the intervention. Method of measurement: measuring the test time.;Physical activities rate. Timepoint: Before and after the intervention. Method of measurement: Via The Physical Activity Scale for the Elderly questionnaire /PASE.;Physical health condition. Timepoint: Before and after the intervention. Method of measurement: using PAR-Q questionnaire.;Maximal Strength. Timepoint: Before and after the intervention. Method of measurement: 1RM test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Ghardashi Afousi

University of Tehran

ghardashi.a@ut.ac.ir+98 21 8835 1740

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026